Calyxt Inc (NASDAQ:CLXT) CEO James Blome Sells 3,495 Shares
Calyxt Inc (NASDAQ:CLXT) CEO James Blome sold 3,495 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.65, for a total transaction of $16,251.75. Following the sale, the chief executive officer now directly owns 198,057 shares in the company, valued at approximately $920,965.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
James Blome also recently made the following trade(s):
- On Monday, June 29th, James Blome sold 2,902 shares of Calyxt stock. The shares were sold at an average price of $5.01, for a total transaction of $14,539.02.
NASDAQ CLXT opened at $4.41 on Friday. Calyxt Inc has a 52-week low of $2.40 and a 52-week high of $9.77. The company has a debt-to-equity ratio of 0.35, a quick ratio of 8.80 and a current ratio of 9.38. The company has a market capitalization of $152.32 million, a P/E ratio of -3.34 and a beta of 2.41. The company has a fifty day moving average of $4.90 and a 200-day moving average of $4.85.
Large investors have recently modified their holdings of the stock. Oppenheimer & Co. Inc. purchased a new position in Calyxt in the 1st quarter worth $47,000. UBS Group AG raised its position in Calyxt by 40.4% in the 4th quarter. UBS Group AG now owns 14,296 shares of the company’s stock worth $100,000 after purchasing an additional 4,116 shares during the period. Two Sigma Investments LP purchased a new position in Calyxt in the 1st quarter worth $61,000. Bank of New York Mellon Corp raised its position in Calyxt by 15.8% in the 1st quarter. Bank of New York Mellon Corp now owns 26,097 shares of the company’s stock worth $86,000 after purchasing an additional 3,563 shares during the period. Finally, Wells Fargo & Company MN raised its position in Calyxt by 26.9% in the 1st quarter. Wells Fargo & Company MN now owns 45,933 shares of the company’s stock worth $153,000 after purchasing an additional 9,733 shares during the period. Institutional investors own 23.93% of the company’s stock.
CLXT has been the topic of a number of research analyst reports. Canaccord Genuity initiated coverage on shares of Calyxt in a research report on Tuesday. They set a “buy” rating and a $8.00 price target on the stock. National Securities reaffirmed a “buy” rating and set a $10.00 price target on shares of Calyxt in a research report on Friday, May 8th. BMO Capital Markets cut shares of Calyxt from an “outperform” rating to a “market perform” rating and cut their price target for the company from $13.00 to $7.00 in a research report on Friday, May 8th. Zacks Investment Research cut shares of Calyxt from a “buy” rating to a “hold” rating in a research report on Monday, June 8th. Finally, Wells Fargo & Co cut their price target on shares of Calyxt from $6.00 to $4.00 and set an “equal weight” rating on the stock in a research report on Friday, May 15th. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Calyxt has a consensus rating of “Hold” and a consensus target price of $6.88.
Calyxt Company Profile
Calyxt, Inc, a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for agriculture in the United States. It engages in the development of high oleic and low linolenic soybean product candidates; high fiber wheat; improved quality alfalfa product candidates; and cold storable and reduced browning potatoes.
Further Reading: How are Outstanding Shares Different from Authorized Shares?
Receive News & Ratings for Calyxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt and related companies with MarketBeat.com's FREE daily email newsletter.